The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

CDDF Annual Conference 2026

Cancer Clinical Research in a Changing Global Environment

9 – 11 February 2026, Hybrid Conference

Presentations

SESSION 1: What’s hot in Global Clinical Development?

International Coalition of Medicines Regulatory Authorities (ICMRA) perspective – Emer Cooke (EMA, NL)

FDA Perspective – Nicole Gormley (FDA, US)

SESSION 2: CDDF/AAADV joint session on Representativeness in Global Clinical Trials

Patients’ perspective – Marianna Vitaloni (Digestive Cancer Europe, ES)

Designing Clinical Research that Addresses Patients’ Needs – Regulatory Perspective – Lola Fashoyin-Aje (Independent Consultant, US)

Statistician perspective – Murielle Mauer (EORTC, BE)

SESSION 3: Driving research using health data

Setting the scene: use of PROs in oncology trials – Christina Yap (The Institute of Cancer Research, UK)

Patient Experience Data in development programs and regulatory decision-making – Claire Espinasse (EMA, NL)

HTA perspective: PROs in joint clinical assessment – Lisa Vervueren (INAMI, BE)

Patients’ perspective – Jan Geissler (Patvocates, DE)

Industry perspective of patient-reported outcomes in oncology: Values, Challenges and Optimization – Sheetal Patel (Genentech, US)

SESSION 4: The Use of Big Data in Oncology Drug Development

Set the scene – Mark Lawler (CDDF, UK)

Academic perspective – Aedin Culhane (University of Limerick, IE)

EMA perspective – Alexandra Pacurariu (EMA, NL)

Patient perspective – Gilliosa Spurrier-Bernard (MPNE, FR)

Industry perspective – Simon Bates (Johnson & Johnson, UK) – no slides provided

SESSION 5: Diversity in Clinical Trials

Set the scene – Fergus Sweeney (CDDF, IE)

Academic perspective – Pauline Reiß (University of Bochum, DE)

Industry perspective on clinical development planning – Sarah Bentouati (Roche, CH)

EU regulatory perspective – Harald Enzmann (BfArM, DE)